Kalambokis, Georgios N <br/><br/>
Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites.  [electronic resource] 

 -  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association  Jul 2012 
 - 815-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>1542-7714 
<br/><br/><label>Standard No.: </label>10.1016/j.cgh.2012.02.025  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anti-Bacterial Agents--administration & dosage<br/>Ascites--drug therapy<br/>Blood Pressure<br/>Cardiac Output<br/>Endotoxins--blood<br/>Hemodynamics--drug effects<br/>Humans<br/>Interleukin-6--blood<br/>Kidney--drug effects<br/>Kidney Function Tests<br/>Liver Cirrhosis, Alcoholic--complications<br/>Male<br/>Middle Aged<br/>Pilot Projects<br/>Prospective Studies<br/>Renin--blood<br/>Rifamycins--administration & dosage<br/>Rifaximin<br/>Treatment Outcome<br/>Tumor Necrosis Factor-alpha--blood